Posts filtered by tags: Shire[x]


Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More

Diabetes drugs are Eli Lilly’s bread and butter, but the pharmaceutical giant hasn’t lost its appetite for cancer drugs. It grabbed hold of a few more this week by betting $8 billion on Loxo Oncology.Loxo (NASDAQ: LOXO) has made a name for itself by becoming one of just two companies ever to earn an FDA approval for a drug that targets a tumor’s DNA fingerprint, no matter where in the body that cancer is found. The drug, larotrectinib, targets rare tumor abnormalities known as NTRK fusions. The...
Tags: Deals, Startups, Ipo, Cancer, Trends, Medicare, SEC, Fda, National, GlaxoSmithKline, Allergan, Shire, Biotech, Medical Device, Postpartum Depression, Bernie Sanders

Takeda unlikely to sell OTC drug business - CEO

Takeda Pharmaceutical is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it closes a $59 billion takeover of London-listed Shire, Chief Executive Christophe Weber said on Monday.
Tags: London, Money, businessNews, Shire, Takeda, Takeda Pharmaceutical, Christophe Weber

Where I’m At: January, 2019 – Pattaya edition

Greetings from Pattaya and happy new year! Hope you all have a great 2019. Where I’m At is my monthly summary of where I’ve been and other site news. I had a busy travel month, and the more I travel the less I write, so more in-depth articles will be posted later. Where I’ve Been Saigon View this post on Instagram An old beauty in District 5, Saigon. A post shared by James Clark (@nomadicnotes) on ...
Tags: Travel, Hong Kong, Thailand, Shire, Bangkok, Macau, Da Nang, Pai, Where I'm At, Chiang Mai, Anthony Bourdain, Pattaya, Saigon, Agoda, Nha Trang, JAMES CLARK

Alternate Histories: The Two Film Adaptations of ‘Lord of the Rings’ on Their 40th and 15th Anniversaries

2018 is a major anniversary for The Lord of the Rings on screen. It’s been 40 years since the release of Ralph Bakshi’s animated version, and 15 years since the completion of Peter Jackson’s live-action trilogy. This dual anniversary – in addition to an imminent new adaptation on Amazon – makes for a fine opportunity to look at the two versions that exist so far. How do they differ? How do they align? Looking back at both from a distance, the answers surprised even me. A Halfling Half-Mo...
Tags: Amazon, Movies, John Lennon, Christopher Lee, Features, Harvey Weinstein, New Zealand, Stanley Kubrick, John, Shire, Jackson, Bilbo, Peter Jackson, Middle Earth, Tolkien, Ralph Bakshi

How to Find the Discipline and Focus to Write

This article is by Anne Marie Gazzolo. I am a master procrastinator and gold-medal winner in the art of distracting myself from what is important. I was so daunted by the amount of notes to gather into a cohesive first draft of my new book, Chosen, about the journeys of Bilbo and Frodo, I put it off again and again. I finally started in January 2017 after I was over the worst of the flu. I had some downtime while I recovered and used it wisely. And guess what? I finished my first draft far soon...
Tags: Facebook, Writing Life, Shire, Resistance, Bilbo, Long Way Home, Frodo, Steven Pressfield, Anne Marie Gazzolo, Pressfield

Healthcare deals hit an all-time record in 2018. See the 7 biggest tie-ups that could change how we buy drugs and treat diseases.

Healthcare dealmaking hit a record this year, and the transactions could reshape how we pay for our prescriptions and treat diseases. Big pharma companies, health insurers, and care providers have agreed to about $421 billion in transactions this year, according to data from Refinitiv. That's a record high, and amounts to 11 percent of all M&A this year. The tally from Refinitiv counts deals when they're announced, though not all transactions are ultimately completed. The dollar figures includ...
Tags: Japan, US, Trends, Cigna, GlaxoSmithKline, Novartis, Shire, GSK, Takeda, Refinitiv

Bio Roundup: ASH Wrap, CRISPR Baby Fallout, Moderna’s Record IPO

The biggest yearly meeting for blood disease research has come and gone, and yet the stories to come out of the American Society of Hematology’s gathering in San Diego represent just a fraction of what happened in biopharma this week.Even if ASH wasn’t on your radar, the CRISPR baby saga—the apparent birth of gene edited twin girls in China that shocked the life sciences world a few weeks ago—rolled on. One massive buyout was signed, and another even bigger one inched closer to being finalized....
Tags: Deals, Startups, China, Ipo, Trends, IPOs, People, Vc, Adhd, San Diego, Astrazeneca, Fda, National, GlaxoSmithKline, Novartis, Ash

Takeda and Shire shareholders back £46bn drugs takeover

Shareholders in Shire and Takeda vote in favour of creating one of the world's biggest pharma groups.
Tags: Business, Shire, Takeda

Shareholders agree to Takeda's $60bn Shire acquisition

Japanese drug giant Takeda's mammoth $60-billion takeover of Irish pharmaceuticals firm Shire has been approved by both sets of shareholders, the pair said Wednesday. The proposed purchase, worth the equivalent of 51.5 billion euros or £46 billion, represents the biggest ever foreign takeover by a Japanese firm. A group of rebel Takeda investors, including members of the founding family, had attempted to thwart the deal but were outvoted at an extraordinary shareholders' meeting held in the w...
Tags: Science, Shire, Osaka, Takeda

Takeda clears key hurdle as investors back $59 billion Shire deal

Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire, creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt.
Tags: London, Money, businessNews, Shire, Takeda, Takeda Pharmaceutical

Takeda investors back $59 billion Shire deal, but wary of debt load

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.
Tags: London, Money, businessNews, Shire, Takeda, Takeda Pharmaceutical

Takeda shareholders approve $59 billion Shire buy but are wary of debt load

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.
Tags: London, Money, businessNews, Shire, Takeda, Takeda Pharmaceutical

Takeda shareholders agree to $60 bn Shire acquisition

Shareholders at Japanese drug giant Takeda on Wednesday approved a plan to buy Irish pharmaceuticals firm Shire in a deal worth around $60 billion, the biggest foreign takeover ever by a Japanese firm. A group of rebel investors, including members of the founding family, tried to thwart the deal but were outvoted at an extraordinary shareholders' meeting held in the western city of Osaka where the company has its headquarters. The scheme was "approved as originally proposed", said a statement...
Tags: Science, Shire, Osaka, Takeda

Takeda shareholders back £46bn Shire takeover

Investor approval paves the way for Japan's largest overseas acquisition and create a global drugs giant.
Tags: Japan, News, Shire, Takeda

Takeda gets shareholder approval for £46bn Shire takeover

The move paves the way for Japan's largest overseas acquisition and would create a global drugs giant.
Tags: Japan, UK, News, Shire, Takeda

Takeda shareholders give nod for $59 billion Shire acquisition

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.
Tags: London, Money, businessNews, Shire, Takeda, Takeda Pharmaceutical

Takeda's Shire takeover to bring $963 million fee bonanza

Banks, law firms and other advisers stand to earn up to $963 million in fees from Takeda Pharmaceutical's $62 billion takeover of drugmaker Shire , according to documents for the deal published on Monday.
Tags: Money, businessNews, Shire, Takeda, Takeda Pharmaceutical

100 years on we shall remember them: Britain commemorates its WWI dead

They may no longer be with us - the last of their number, Harry Patch, died in 2009, aged 111 - but we will remember them. Around the country thousands of people will pay tribute on Sunday to those who died on foreign soil or at sea for their country, and those at home who endured the anguish and hardship of global war. On the 100th anniversary of the Armistice events will take place in every corner of the British Isles to commemorate the sacrifice of a generation during the First World War, whi...
Tags: UK, News, Wales, France, Germany, India, Britain, Theresa May, Victoria Cross, Cenotaph, Yorkshire, Cardiff, Devon, Belfast, Westminster, Portsmouth

Ten Reasons Why The Hobbit Trilogy is Worthwhile

Ten Reasons Why the Hobbit Trilogy is Worthwhile The Lord of the Rings trilogy is one of the greatest cinematic achievements of all time.  In terms of fantasy epics, the genre has never been done better. What Peter Jackson was able to pull off with J.R.R. Tolkien’s opus is something we all may never see again in our lifetime.  So when The Hobbit films were announced, all the Middle Earth nerds were incredibly excited.  However, when the first installment was released in December 2012, th...
Tags: Amazon, Movies, Benedict Cumberbatch, The Hobbit, Ed Sheeran, Guillermo Del Toro, Martin Freeman, Shire, Smaug, Jackson, Bilbo, Peter Jackson, Middle Earth, Billy Boyd, Richard Armitage, Tolkien

Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources

Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.
Tags: London, Money, Eu, businessNews, Shire, Takeda, Takeda Pharmaceutical

Exclusive: EU regulators to clear $62 billion Takeda, Shire deal - source

EU antitrust regulators are set to approve Japanese drugmaker Takeda Pharmaceutical's $62-billion offer for London peer Shire on condition that Shire sells a drug it has in development, a person familiar with the matter said on Friday.
Tags: London, Money, Eu, businessNews, Shire, Takeda Pharmaceutical, Takeda Shire

Mirum Pharmaceuticals Launches with $120M to Advance Liver Drugs

Serial entrepreneur Mike Grey is launching a biotech enterprise with $120 million in new funding to advance two investigational liver disease drugs—one of which he has worked to develop before.Called Mirum Pharmaceuticals, the startup is developing a compound, maralixibat, to treat Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), genetic liver disorders that affect primarily children. Mirum plans to move maralixibat, its lead drug, into a Phase 3 trial next yea...
Tags: Deals, Startups, Entrepreneurship, Trends, Vc, San Diego, Fda, Pharmaceuticals, Allergan, Shire, Biotech, Liver disease, Venture Funding, New Enterprise Associates, Life Sciences, Grey

Takeda CEO confident of investor backing for $62 billion Shire deal

The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its $62 billion acquisition of London-listed Shire, despite some shareholders' fears about the resulting debt burden.
Tags: Japan, London, Money, businessNews, Shire, Takeda, Takeda Pharmaceutical

The Best Feminist Books To Spark Your Awakening

So, you want to be a feminist? You've come to the right place. There's no better way to get educated, get angry, get inspired, and get impassioned than by cracking open a book.Each of the novels, memoirs, and essay collections will draw you in with quality writing and even more compelling stories. These are books that give time to the stories, lives, and truths of women. Each is worth a read, and then worth buying for all your friends to read, too. Because once you've awakened, there's no going...
Tags: Facebook, Fashion, Music, England, Hollywood, Lorde, Nicki Minaj, Virginia, Disney, America, Rebecca, Gay, Lena Dunham, New Orleans, Monaco, Scarlett Johansson

Peter Jackson Isn’t Involved With the ‘Lord of the Rings’ TV Series, But He Is Excited to Watch It

No, Peter Jackson isn’t involved with the Lord of the Rings TV series. Instead, JD Payne and Patrick McKay are developing the new show inspired by the works of J.R.R. Tolkien. And Jackson can’t wait to see what they come up with. The filmmaker says that the series will give him a chance to experience Lord of the Rings in a way he never could with his own movies. There’s been some confusion regarding Peter Jackson’s involvement in Amazon’s super-expensive Lord of the Rings TV series. First, a...
Tags: Amazon, Television, Movies, Fantasy, Star Trek, Shire, Jackson, Viggo Mortensen, Peter-Jackson, Tolkien, McKay, J R R Tolkien, Payne, Frodo, Aragorn, Patrick McKay

10 of the best historical walks in the UK: readers’ travel tips

From a Tolkien trail in Lancashire to Gloucestershire’s war poet walks, our tipsters reveal trips through landscapes brimming with historyStart the Tolkien Trail at the hamlet of Hurst Green, home to three pubs and no shops, and head north towards the 500-year-old Stonyhurst College, which schooled Sir Arthur Conan Doyle, Gerard Manley Hopkins and at which JRR Tolkien stayed numerous times throughout his life. The area around the college is said to have inspired the Shire, the land of the Hobbit...
Tags: Travel, UK, Heritage, Preston, Shire, Top 10s, Cultural Trips, Tolkien, Walking Holidays, Lancashire, Gloucestershire, Chris, United Kingdom Holidays, Cromwell, Pendle Hill, Stonyhurst College

Bio Roundup: CRISPR Ruling, “America’s Nobels,” IPOs & More

The long running patent feud over CRISPR-Cs9 gene editing appears to be over, just as U.S. biotech companies gear up for the first human tests of the landmark technology.This week, a federal appeals court . The decision by the three-judge panel essentially said that the Broad patent was different enough so as not to infringe on a patent awarded to a rival group at the University of California, Berkeley. Berkeley could appeal to the U.S. Supreme Court, but it’s not yet clear if it... Read mor...
Tags: Deals, Startups, Ipo, America, Trends, Investing, Merck, Fda, National, Apple Watch, Parkinson's Disease, Shire, University Of California Berkeley, Biotech, General Atlantic, Pneumonia

Gilead Partners with Precision Bio in Search of Gene-Editing HBV Cure

Gilead Sciences is turning to gene editing in its effort to develop a cure for hepatitis B virus infections—DNA-cutting enzymes that would eliminate the virus in the body, something current hep B drugs can’t do.Foster City, CA-based Gilead (NASDAQ: GILD) is partnering with Precision Biosciences, a company that has used its proprietary gene-editing platform to develop products for both agriculture and human health. No upfront payments were disclosed, but if the alliance results in commercialized...
Tags: Deals, Startups, Cancer, San Francisco, Trends, Shire, Biotech, Centers For Disease Control And Prevention, Crispr, Life Sciences, Clinical Trials, Gilead Sciences, Durham NC, Gilead, National blog main, San Francisco blog main

The Goosey Quilters Exhibition 2018

If you are anywhere near the Shire this weekend then please do stop by in Tavistock for the Goosey Quilters exhibition.  Thursday lunchtime to Saturday afternoon, nice quilts, nice cakes, nice things to buy (I think I'm helping to woman the sales table and will probably do some sink/ door/raffle/stewarding duty too). Having set up the group with two friends back in 1986, before work and life got in the way, it was good to find the group was still there when I found the time to rejoin a coupl...
Tags: Books, New York, Shire, Dyson, Dovegreyreader, Bookhound, Tavistock, Strand Bookshop

Bio Roundup: EpiPen Shortage, Bluebird’s Bet, Biotech IPOs & More

It’s back-to-school season and that means it’s time to load up on school supplies. For many students and schools, one crucial item is in high demand but hard to come by: the EpiPen.Some schools stock the epinephrine autoinjectors so they can respond quickly to a student’s allergic reaction to food. Though the autoinjectors are sold by Mylan (NASDAQ: MYL), they’re made by a Pfizer (NYSE: PFE) subsidiary whose manufacturing problems have disrupted shipments. A generic version from Teva Pharmaceut...
Tags: Deals, Startups, Trends, Investing, Merck, IPOs, Mit, Food And Drug Administration, Fda, National, Pfizer, Vaccine, Allergan, Shire, Immunotherapy, Abbvie